Yifan Qing

Ms. Yifan Qing


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
YQYifan Qing
Yifan Qing
WZWenbo Zhao
Wenbo Zhao
LXLiangliang Xue
Liangliang Xue
YLYu Luo
Yu Luo
YGYuhao Gao
Yuhao Gao
LLLiang Leng
Liang Leng
Severe respiratory inflammation or viral infections can lead to acute lung injury (ALI), a disease characterized by diffuse inflammatory injury of the pulmonary epithelium and endothelium. Cepharanthine (CEP) is reported as a promising drug candidate due to its antiviral properties. However, CEP exhibits poor solubility and low bioavailability. Therefore, we developed a novel liposome, named CEP@LP-MCCR2, which integrates the advantages of cell membranes and lipid materials, to achieve effective accumulation of CEP in inflamed lungs. It exhibits a 1.73-fold increase in lung accumulation at 24 h in vivo, a 4.56-fold increase in cellular uptake in MLE-12 cells. CEP@LP-MCCR2 is equipped with a CCR2-overexpressed surface, enabling it to selectively neutralize elevated levels of CCL2, which is related to ALI, thereby reducing macrophage infiltration, thereby reducing the spread of inflammation, such as a reduction in levels of key pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6). CEP@LP-MCCR2 could suppress M1 macrophage polarization, which led to a marked decrease in iNOS and an increase in Arg1. It upregulated the expression of junctional proteins E-cadherin and Occludin, indicating potential recovery of the pulmonary epithelial barrier. RNA sequencing analysis implied the potential of CEP@LP-MCCR2 to inactivate the TNF/NF-κB signaling axis.

Verified
Journal Article
Open access
PDF file
ZBZenghao Bi
Zenghao Bi
YLYuting Liang
Yuting Liang
XTXinyu Tang
Xinyu Tang
YSYun Shu
Yun Shu
ZXZhuangyuan Xie
Zhuangyuan Xie
SCShilin Chen
Shilin Chen
Benzylisoquinoline alkaloids (BIAs) exhibit diverse biological activities, such as neuroprotective effects. The delta-opioid receptor (DOR) has emerged as a promising therapeutic target due to its potential role in enhancing neuroprotection and regeneration. However, reports on the binding of BIAs to the DOR remain scarce. Here, neferine, a BIA from Nelumbo nucifera, as a potential DOR agonist. Molecular docking ranked neferine among the top of 15 BIAs. Initial binding was detected by cellular membrane chromatography and quantitatively confirmed by bio-layer interferometry, with a KD value of 37.4 μM. ONE vector G protein Optical biosensor revealed that Gi2, Gi3 and GZ signaling could be activated by neferine through DOR modulation. Consistent with the Gi/z activation, neferine dose-dependently inhibited cAMP accumulation with an EC50 of 0.25 µM. Transcriptomic analysis in DOR-overexpressing HEK293T cells indicated that neferine stimulation predominantly regulates gene networks governing cell cycle and stress adaptation. However, direct transcriptional signature for neuroprotection was not predominant in our system, suggesting that DOR signaling may exhibit context-dependent effects. In conclusion, we identified the neferine as a natural DOR agonist through in silico and in vitro approach, providing a reference for further investigation into its pharmacological potential.